Eurobio Scientific

STRONG GROWTH OF 2019 ANNUAL RESULTS - Seite 3

COVID-19 update

In the context of the health crisis linked to the COVID-19 epidemic, Eurobio Scientific has succeeded in rapidly making available to public and private laboratories a range of effective tests, imported and produced in-house. To this end, in addition to the measures intended to limit the infection of its employees by the Coronavirus, the Group has maintained and implemented an organization in order to ensure both the continuity of its distribution logistics which activity increased substantially, the installation and maintenance of instruments in hospital and private laboratories, and the manufacture of proprietary test kits.

Since the start of the crisis, the products sold have been molecular biology tests intended to identify the presence of the virus. This is the Allplex Coronavirus test by Korean partner Seegene, of which Eurobio Scientific is the exclusive distributor in France, and the proprietary EBX 041 SARS CoV2 test, designed and produced in-house.

To these molecular biology tests will gradually be added serological tests which objective is to identify in the blood the presence or absence of antibodies directed against the SARS CoV2 virus, for which Eurobio Scientific is ready with the launch of a first MagLumi COVID-19 automated serological test from its Chinese partner SNIBE.

Eurobio Scientific has so far recorded a total amount of orders of around 14 million euros for all tests and equipment related to Covid-19, of which 7 million euros have already been invoiced. The fulfillment of these orders will depend on the ability of suppliers to ensure the supply of raw materials or necessary tests, and of carriers to ensure shipments in a very constrained general geopolitical environment. The distribution of this turnover between the different types of tests will depend on future government decisions, in particular on deconfinement strategies.

As health services have focused primarily on the fight against Covid-19, a number of routine medical procedures have been canceled or postponed. In this context, the company anticipates a slowdown in its activity outside of Covid-19, with a reduction in turnover to levels similar to those usually observed during holiday periods. To date, the increased activity linked to Covid-19 has more than compensated this slowdown, and, with a continuation of current trends, the company now expects a marked increase in its turnover in 2020.